^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    E-selectin antagonist

    Related drugs:
    8ms
    Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients (clinicaltrials.gov)
    P1, N=12, Completed, Apollomics Inc. | Recruiting --> Completed | Trial completion date: Feb 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    cytarabine • uproleselan (APL-106)
    8ms
    Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML (clinicaltrials.gov)
    P3, N=140, Terminated, Apollomics Inc. | Trial completion date: Feb 2024 --> Aug 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Aug 2024; In light of the strategic realignment of the company's development focus, it has been determined to discontinue the further development of Uproleselan Injection.
    Trial completion date • Trial termination • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    cytarabine • uproleselan (APL-106)
    10ms
    NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | N=22 --> 8 | Trial completion date: Dec 2026 --> May 2026 | Trial primary completion date: Dec 2026 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    SELL (Selectin L)
    |
    cytarabine • leucovorin calcium • fludarabine IV • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)
    over1year
    Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=37, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2024 | Trial primary completion date: Dec 2026 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    cytarabine • cladribine • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)
    over1year
    NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    SELL (Selectin L)
    |
    cytarabine • leucovorin calcium • fludarabine IV • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)
    over1year
    Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML (clinicaltrials.gov)
    P1, N=1, Terminated, Malika Kapadia | Phase classification: P1/2 --> P1 | N=28 --> 1 | Trial completion date: Dec 2028 --> Dec 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Oct 2023; On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Pre-transplantation
    |
    RUNX1 (RUNX Family Transcription Factor 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    clofarabine • fludarabine IV • busulfan • uproleselan (APL-106)
    over1year
    NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    SELL (Selectin L)
    |
    cytarabine • leucovorin calcium • fludarabine IV • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)
    over1year
    Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P3, N=388, Terminated, GlycoMimetics Incorporated | Trial completion date: Dec 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Trial failed to meet primary endpoint.
    Trial completion date • Trial termination • Combination therapy
    |
    cytarabine • uproleselan (APL-106)
    over1year
    Selectins in Biology and Human Disease: Opportunity in E-selectin Antagonism. (PubMed, Cureus)
    E-selectin plays a unique role in leukocyte activation, making it an attractive target for intervention, for example, in sickle cell disease (SCD). This review summarizes selectin biology and pathology, structure and ligand binding, and selectin antagonists that have reached clinical testing with an emphasis on E-selectin.
    Review • Journal
    |
    SELP (Selectin P)
    almost2years
    Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia. (PubMed, Br J Haematol)
    Finally, we present clinical evidence showing that BM myeloid cells from higher risk MDS and AML patients have the potential to bind E-selectin, and these cells are more abundant in 5-azacitidine-non-responsive patients. The collective data provide a strong rationale to evaluate 5-azacitidine in combination with the E-selectin antagonist, uproleselan, in this patient population.
    Journal
    |
    FUT7 (Fucosyltransferase 7)
    |
    azacitidine • uproleselan (APL-106)
    2years
    Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • cladribine • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)
    over2years
    Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML) (ASH 2023)
    Uproleselan combined with Cladribine + LDAC was well-tolerated with minimal therapy-related AEs – allowing a safe approach to marrow blast reduction and disease control in preparation for a potential allogeneic SCT. We are currently determining the relationship of plasmatic e-selectin concentration and response to treatment.
    Clinical
    |
    TP53 (Tumor protein P53) • RUNX1 (RUNX Family Transcription Factor 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2)
    |
    TP53 mutation • TET2 mutation • SRSF2 mutation
    |
    cytarabine • cladribine • uproleselan (APL-106)